Disodium Pamidronate Injection 30mg/60mg/90mg Dry Powder Injections Vial

What is Disodium Pamidronate Injection 30mg/60mg/90mg Dry Powder Injections Vial?

Pamidronate disodium is a bisphosphonate medicine that inhibits bone resorption. It is used in selected conditions involving increased bone turnover or elevated blood calcium, according to the approved product information. The supplied listing specifies 30 mg, 60 mg and 90 mg vial presentations. The precise formulation, approved route, preparation instructions and indications should be verified against the manufacturer’s documentation.

Uses / Indications

Pamidronate disodium is used for selected conditions involving elevated blood calcium or increased bone resorption. According to the referenced prescribing information, approved indications include:

• Hypercalcaemia of malignancy: Moderate to severe elevation of blood calcium associated with cancer.

• Paget’s disease of bone: Moderate to severe disease affecting normal bone remodelling.

• Osteolytic bone lesions: Bone lesions associated with multiple myeloma or osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic treatment.

  

  Access Data

  +1

These indications are based on specific prescribing information and may differ by country and formulation. Confirm the approved indications for the product intended for export.

6. Benefits

• Bone resorption inhibition: Helps reduce excessive bone breakdown in approved clinical settings.

• Management of elevated blood calcium: Has an established role in treating selected cases of malignancy-associated hypercalcaemia.

• Oncology-related applications: May be used for specified osteolytic bone complications associated with cancer.

• Defined strength range: The supplied product listing specifies 30 mg, 60 mg and 90 mg presentations.

• Pharmaceutical sourcing support: Kelar Pharmachem India can support B2B product enquiries, subject to confirmation of availability and destination-market requirements.

These are established pharmacological and clinical characteristics, not guarantees of treatment outcomes.

7. Side Effects

Common or recognised side effects

Reported adverse reactions may include:

• Fever or flu-like symptoms.

• Nausea and vomiting.

• Headache.

• Bone or musculoskeletal pain.

• Reactions at the infusion site.

• Reduced blood calcium or phosphate levels.

• Fatigue.

The adverse-effect profile depends on the indication, patient characteristics and treatment regimen.

Less common or serious side effects

Important risks include:

• Renal toxicity: Deterioration in kidney function, potentially progressing to renal failure.

• Electrolyte disturbances: Hypocalcaemia, hypophosphataemia, hypomagnesaemia and other electrolyte abnormalities.

• Osteonecrosis of the jaw: A serious complication associated with bisphosphonate treatment, particularly in relevant oncology settings.

• Atypical femoral fractures: Rare fractures that may occur with minimal trauma.

• Severe hypersensitivity: Including anaphylaxis.

• Other serious reactions: Clinically significant abnormalities may occur depending on the patient’s condition and concurrent treatment.

Suspected serious adverse effects require prompt medical assessment. Renal function and relevant biochemical parameters should be monitored according to the approved product information.

8. How Does It Work?

Pamidronate disodium belongs to the bisphosphonate class of medicines. It binds to bone mineral and inhibits osteoclast-mediated bone resorption, reducing the breakdown of bone tissue.

This action can help reduce elevated blood calcium associated with malignancy and limit bone resorption in certain approved bone disorders. Its effects and clinical suitability depend on the underlying condition and the approved treatment regimen.

9. Dosage Guidelines

The dosage and administration schedule must be determined by a qualified healthcare professional using the approved product information.

Relevant factors include:

• The condition being treated and its severity.

• The patient’s renal function.

• Blood calcium and other relevant laboratory results.

• The prescribed treatment regimen and clinical response.

• The exact formulation and approved administration instructions.

Do not infer a dose, infusion duration, dilution volume, diluent, final concentration or post-preparation stability from the vial strength alone.

The referenced US prescribing information specifies intravenous administration for its pamidronate products. The route and preparation requirements for the supplied presentation must be verified against its own approved label. Administration should be performed by appropriately qualified healthcare professionals.

10. When Not to Use

Pamidronate disodium should not be used in patients with:

• Known clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates.

• Hypersensitivity to a relevant excipient where it is listed as a contraindication in the approved product information.

• Any other product-specific contraindication identified in the approved prescribing information.

Patients with significant renal impairment, electrolyte disturbances or other relevant medical conditions require careful assessment before treatment. These conditions may require precautions or restrictions rather than constituting an absolute contraindication in every situation.

11. Drug / Product Interactions

Potential interaction considerations include:

• Other nephrotoxic medicines: Concurrent use may increase concern about kidney injury.

• Other bisphosphonates or medicines affecting bone metabolism: The complete treatment regimen should be reviewed to avoid inappropriate duplication.

• Medicines affecting calcium levels: Additional assessment and monitoring may be needed.

• Thalidomide in multiple myeloma: The referenced US prescribing information identifies an increased risk of renal dysfunction with concomitant use.

• Injectable medicines and infusion solutions: Physical compatibility must be confirmed before mixing or co-administration.

  

  PAMIDRONATE DISODIUM injection

  +1

Healthcare professionals should review the patient’s current medicines and relevant laboratory results. Do not mix this product with another medicine in the same vial, syringe or infusion container unless compatibility is confirmed for the exact formulation.

12. Safety Advice

• Use only under qualified medical supervision.

• Verify the product name, strength, batch number and expiry date before use.

• Assess renal function before treatment and follow the prescribed monitoring plan.

• Monitor calcium, phosphate, magnesium and other relevant biochemical parameters.

• Address dental health and preventive dental care where indicated, particularly in patients receiving oncology treatment.

• Report severe muscle cramps, unusual weakness, reduced urine output, jaw symptoms or thigh or groin pain promptly.

• Seek urgent medical assessment if signs of a serious allergic reaction occur.

• Do not use for self-medication or unsupervised administration.

13. General Instructions

• Inspect the vial and packaging for damage before preparation.

• Read the approved product label and package insert.

• Use only the specified diluent and preparation procedure.

• Follow appropriate aseptic preparation procedures.

• Confirm the intended route and infusion requirements from the approved instructions.

• Do not assume compatibility with other medicines or infusion solutions.

• Check the prepared solution against the manufacturer’s specified acceptance criteria.

• Follow the approved instructions for use after reconstitution or dilution.

• Dispose of unused medicine and preparation materials according to applicable procedures.

Reconstitution volumes, dilution instructions, infusion rates, compatibility and post-preparation stability must be verified from the manufacturer’s product documentation.

14. Special Dietary / Lifestyle Tips

No universal dietary regimen can be recommended from the supplied product details alone.

• Follow the treating clinician’s advice about calcium, vitamin D and other supplements.

• Attend recommended blood tests and clinical follow-up.

• Inform the healthcare professional about all medicines and supplements being used.

• Maintain appropriate oral hygiene and seek dental advice where indicated.

• Report new jaw symptoms, persistent bone pain or unusual thigh or groin pain.

• Follow individual fluid-intake recommendations, particularly if kidney function or calcium levels are affected.

• Do not start or discontinue supplements or treatment without medical advice.

15. Comparison with Other Treatments

These treatments are not automatically interchangeable. Selection depends on the underlying condition, treatment objectives, renal function, other medical factors and applicable clinical guidance.

16. Precautions & Warnings

• Renal impairment: Pamidronate can adversely affect kidney function. Renal assessment and monitoring are important before and during treatment.

• Electrolyte disturbances: Monitor calcium, phosphate, magnesium and other relevant parameters as directed.

• Dental health: Osteonecrosis of the jaw has been reported with bisphosphonates. Appropriate dental assessment and preventive care may be necessary.

• Pregnancy: Pamidronate may pose a risk to the developing foetus. Pregnancy status and potential reproductive risks require medical assessment.

• Breastfeeding: Follow the applicable product information and advice from the treating clinician.

• Atypical fractures: Persistent thigh or groin pain requires clinical evaluation.

• Concurrent medicines: Review medicines that may affect renal function, calcium balance or overall treatment safety.

• Product-specific formulation: Confirm the approved route, preparation requirements and storage conditions before use.

These precautions are consistent with recognised warnings in pamidronate prescribing information. Their application should be assessed for the specific product and patient.

17. Can I Use It With Other Medicines or Antibiotics?

The suitability of pamidronate disodium with other medicines depends on the patient’s clinical condition, current treatment and the exact products involved.

Healthcare professionals should review:

• Prescription and non-prescription medicines.

• Other medicines that may affect kidney function.

• Treatments affecting calcium levels or bone metabolism.

• Medicines used for cancer and related complications.

• Any proposed injectable combination or infusion solution.

Clinical drug interactions and physical compatibility during preparation are different issues. Do not mix pamidronate disodium with another injectable medicine unless compatibility is established by reliable product-specific documentation.

18. Storage

Store according to the manufacturer’s approved product labelling. Refer to the product packaging or package insert for the applicable storage conditions.

The storage temperature, light-protection requirements, shelf life and stability after reconstitution or dilution have not been supplied for this specific product. Confirm these details against the manufacturer’s documentation before publication.

19. Frequently Asked Questions (FAQs)

1. What is Disodium Pamidronate Injection used for?

Pamidronate disodium is used for selected conditions such as malignancy-associated hypercalcaemia, Paget’s disease of bone and certain cancer-related osteolytic bone lesions, subject to the approved product indications.

2. What strengths are listed for this product?

The supplied product name lists 30 mg, 60 mg and 90 mg presentations. Confirm the available strengths and formulation against the approved product documentation.

3. What type of medicine is pamidronate disodium?

It is a bisphosphonate that inhibits osteoclast-mediated bone resorption.

4. Which route of administration is used?

The referenced US product information specifies intravenous administration. Confirm the approved route and administration requirements for the particular product before use.

5. How should the dry powder be reconstituted?

Follow the manufacturer’s approved instructions for the specific formulation. The diluent, preparation procedure, dilution volume and final concentration must not be assumed.

6. What monitoring is needed during treatment?

Monitoring may include renal function, blood calcium, phosphate, magnesium and other relevant laboratory parameters. Dental assessment may also be appropriate, depending on the clinical circumstances.

7. How should the product be stored?

Follow the storage conditions specified in the approved product labelling. Storage requirements and stability after preparation must be verified for the particular formulation.

8. Is the product available for pharmaceutical export?

Availability, packaging options, order quantities and destination-market documentation should be confirmed with Kelar Pharmachem India. No specific export approval or certification is implied by this listing.